PT  - JOURNAL ARTICLE
AU  - Slavova, Nedelina
AU  - Münger, Robin
AU  - Sanchez-Albisua, Iciar
AU  - Regényi, Maria
AU  - Oesch, Gabriela
AU  - Fluss, Joël
AU  - Hackenberg, Annette
AU  - Lebon, Sébastien
AU  - Maier, Oliver
AU  - Datta, Alexandre
AU  - Bigi, Sandra
AU  - Grunt, Sebastian
AU  - Steinlin, Maja
TI  - Inflammatory Type Focal Cerebral Arteriopathy of the Posterior Circulation in Children: a comparative cohort study
AID  - 10.1101/2023.04.15.23288630
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.15.23288630
4099  - http://medrxiv.org/content/early/2023/04/24/2023.04.15.23288630.short
4100  - http://medrxiv.org/content/early/2023/04/24/2023.04.15.23288630.full
AB  - Background Inflammatory type Focal Cerebral Arteriopathy (FCA-i) in the anterior circulation (AC) is well characterized and the FCA severity score (FCASS) reflects the severity of disease. We identified cases of FCA-i in the posterior circulation (PC) and adapted the FCASS to describe these cases.Methods Patients from the Swiss NeuroPaediatric Stroke Registry (SNPSR) with ischemic stroke in the PC and AC due to FCA-i and available neuroimaging were gathered. Comparison of data regarding Pediatric National Institutes of Health Stroke Scale (pedNIHSS) score and Pediatric Stroke Outcome Measure (PSOM) and FCASS was performed. We estimated infarct size by the modified pediatric Alberta Stroke Program Early Computed Tomography Score (pedASPECTS) in children with AC stroke and the adapted Bernese posterior diffusion-weighted imaging (DWI) score in the PC.Results Thirty-six children with a median age of 6.3 years ([IQR 2.8,8.6; range 0.9,15.6], 21 males, 58.3%) with FCA-i were identified. The total incidence rate was 0.151/100 000/year (95%CI 0.109–0.209). Seven had PC FCA-i and 5 had FCA-i in both circulations. Time to final FCASS was longer in the PC compared to AC, evolution of FCASS did not differ. Initial pedNIHSS was highest in children with FCA-i in the PC with a median of 8.0 (IQR 5.0-18.0), compared to 4.5 (IQR 2.0-8.0) in those with AC FCA-i and 6.0 (IQR 6.0-6.0) with involvement of both AC and PC. Different to the anterior cases PC infarct volume did not correlate with higher discharge, maximum or final FCASS scores (R 0.25, 0.35, 0.54).Conclusion The PC is affected in up to one third of cases of FCA-i. These cases should be included in future investigations on FCA-i. Although it did not correlate with clinical outcome in our cohort, the modified FCASS may well serve as a marker for the evolution of the arteriopathy in posterior FCA-i.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work within the Swiss Neuropaediatric Stroke Registry (SNPSR) has been supported by Novartis Research Foundation, Swiss Heart Foundation, Foundation for neuropsychiatric research, Fondazione Ettore e Valeria Rossi, Anna Mueller Grocholski Stiftung, batzebär Kinderkliniken Bern.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SNPSR has been approved by the competent Ethics Committees and the Swiss Federal Ministry of Health. All registered patients or their legal guardians have provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized raw data is available and can be shared upon reasonable request.